IM

Immunovia AB (publ)STO Immunovia AB Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

0.011

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

IMMNOV.ST Stock Analysis

IM

Uncovered

Immunovia AB (publ) is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-39/100

Low score

Market cap $B

0.011

Dividend yield

Shares outstanding

52.807 B

Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. The company is headquartered in Lund, Skane. The company went IPO on 2015-12-01. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

View Section: Eyestock Rating